PE20190318A1 - Composicion administrable oralmente - Google Patents

Composicion administrable oralmente

Info

Publication number
PE20190318A1
PE20190318A1 PE2018001609A PE2018001609A PE20190318A1 PE 20190318 A1 PE20190318 A1 PE 20190318A1 PE 2018001609 A PE2018001609 A PE 2018001609A PE 2018001609 A PE2018001609 A PE 2018001609A PE 20190318 A1 PE20190318 A1 PE 20190318A1
Authority
PE
Peru
Prior art keywords
composition
orally administrable
micellas
refers
combined
Prior art date
Application number
PE2018001609A
Other languages
English (en)
Inventor
Pankaj Modi
Original Assignee
Ctt Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59722571&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ctt Pharma Inc filed Critical Ctt Pharma Inc
Publication of PE20190318A1 publication Critical patent/PE20190318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION ADMINISTRABLE ORALMENTE QUE COMPRENDE UN AGENTE FORMADOR DE PELICULA FISIOLOGICAMENTE ACEPTABLE TAL COMO PULULANO, METIL CELULOSA, ETIL CELULOSA, CARBOXIMETIL CELULOSA SODICA, ENTRE OTROS, EN UNA CANTIDAD DEL 5 AL 80% EN PESO, COMBINADA CON UNA COMPOSICION MICELAR QUE COMPRENDE UN CANNABINOIDE TAL COMO ACIDO CANNABIDIOL (CBDA), CANNABINOL (CBN), ENTRE OTROS, EN UNA CANTIDAD DE 0.1 A 30% EN PESO DE LA COMPOSICION ENCAPSULADA EN MICELAS; DONDE LAS MICELAS SE FORMAN MEDIANTE UN PRIMER COMPUESTO FORMADOR DE MICELAS, Y OPCIONALMENTE UN SEGUNDO COMPUESTO FORMADOR DE MICELAS, EN UN SOLVENTE ACUOSO FARMACEUTICAMENTE ACEPTABLE QUE COMPRENDE UN SALICILATO DE METAL ALCALINO Y UN EDETATO FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. DICHA COMPOSICION ES EFECTIVA PARA EL SUMINISTRO DE COMPUESTOS TERAPEUTICOS GRANDES TALES COMO PROTEINAS O CANNABINOIDES
PE2018001609A 2016-03-03 2017-02-27 Composicion administrable oralmente PE20190318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/059,444 US11166912B2 (en) 2016-03-03 2016-03-03 Orally administrable composition

Publications (1)

Publication Number Publication Date
PE20190318A1 true PE20190318A1 (es) 2019-03-04

Family

ID=59722571

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001609A PE20190318A1 (es) 2016-03-03 2017-02-27 Composicion administrable oralmente

Country Status (11)

Country Link
US (1) US11166912B2 (es)
EP (1) EP3423037A4 (es)
AU (1) AU2017225927B2 (es)
BR (1) BR112018067586A2 (es)
CL (1) CL2018002474A1 (es)
CO (1) CO2018010549A2 (es)
CU (1) CU20180097A7 (es)
IL (1) IL261479B2 (es)
PE (1) PE20190318A1 (es)
WO (1) WO2017147691A1 (es)
ZA (1) ZA201805802B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US20220079881A1 (en) * 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
WO2018075730A1 (en) * 2016-10-21 2018-04-26 Axim Biotechnologies, Inc. Suppositories comprising cannabinoids
US11951086B2 (en) * 2018-04-03 2024-04-09 Pure Green Pharmaceuticals, Inc. Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2019204630A1 (en) * 2018-04-18 2019-10-24 Leading Edge Pharms Inc. Cbd nanoencapsulation composition and method of use
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10695301B2 (en) * 2018-09-04 2020-06-30 Babak Ghalili Veterinary cannabinoid and menthol compositions and methods
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
CN112569220B (zh) * 2019-09-30 2023-03-07 云南汉盟制药有限公司 四氢次***酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次***酚的药物组合物
GB2587621A (en) * 2019-09-30 2021-04-07 Biofilm Ltd Oral films and a methods for the manufacture and delivery thereof
CN111117125A (zh) * 2019-12-30 2020-05-08 武汉轻工大学 一种复合抗菌膜及其制备方法
CN113116868B (zh) * 2019-12-31 2022-08-19 汉义生物科技（北京）有限公司 四氢次***酚在肺动脉高压的预防和/或治疗中的应用
WO2021243188A1 (en) * 2020-05-29 2021-12-02 Hemp Synergistics Powderized cannabis oil
US11786475B2 (en) * 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
WO2022027053A1 (en) * 2020-07-28 2022-02-03 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
CA3204862A1 (en) 2020-12-09 2022-06-16 I+Med S. Coop. Composition comprising sea water and cannabinoid loaded submicroparticles for pharmaceutical, nutraceutical and cosmetic applications
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2023039587A2 (en) * 2021-09-13 2023-03-16 Arriaga Adan Cannabinoid composition and method of using the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
CA2229286C (en) 1998-02-10 2005-07-26 Generex Pharmaceuticals Inc. Mixed micellar delivery system and method of preparation
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
WO2001072278A2 (en) * 2000-03-30 2001-10-04 Generex Pharmaceuticals Inc. Method for administering insulin to the buccal region
CZ20023154A3 (cs) 2000-03-31 2003-11-12 Pfizer Products Inc. Nové deriváty piperazinu
US6398589B1 (en) 2000-09-07 2002-06-04 Richard A. Congelliere Device for restricting operation of an electrical tool
AU2002952597A0 (en) 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
EP1954242A4 (en) 2005-11-30 2012-08-01 Generex Pharm Inc ORALLY ABSORPTED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CA2624110C (en) 2008-03-27 2010-11-09 Pankaj Modi A rapidly-dissolving orally administrable wafer formulation
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
JP2011526888A (ja) 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
RU2016129536A (ru) 2013-10-31 2018-01-31 Фулл Спектрум Лабораториз, Лтд. Препараты на основе терпенов и каннабиноидов

Also Published As

Publication number Publication date
EP3423037A4 (en) 2019-11-27
ZA201805802B (en) 2019-06-26
CO2018010549A2 (es) 2018-12-14
IL261479A (en) 2021-03-25
BR112018067586A2 (pt) 2019-01-08
AU2017225927B2 (en) 2021-07-01
US20170252300A1 (en) 2017-09-07
IL261479B1 (en) 2023-05-01
IL261479B2 (en) 2023-09-01
CU20180097A7 (es) 2019-05-03
CL2018002474A1 (es) 2019-01-18
EP3423037A1 (en) 2019-01-09
AU2017225927A1 (en) 2018-10-04
US11166912B2 (en) 2021-11-09
WO2017147691A1 (en) 2017-09-08
IL261479A0 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
PE20190318A1 (es) Composicion administrable oralmente
CL2018003452A1 (es) Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.
HRP20201506T1 (hr) Uporaba kanabidiolne kiseline u liječenju epilepsije
BR112018011777A2 (pt) composições de fenfluramina e métodos para o preparo das mesmas
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
PE20200404A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
PE20200383A1 (es) Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados
BR112015025172A2 (pt) composição farmacêutica
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
PE20200698A1 (es) Gel que comprende clorhexidina
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
RU2012103538A (ru) Композиции и способы ингибирования пути jak
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
BR112015007045A2 (pt) composição de cuidado pessoal
BR112015022117A2 (pt) precursor da composição cosmética, composição cosmética para a aplicação tópica, método para a administração de um agente cosmético sólido e amida de triciclodecano
BR112017000052A2 (pt) solução cardioplégica de uso geral (variantes)
EA201200754A1 (ru) Традиционное китайское лекарственное средство, содержащее экстракты дан-шен (danshen) и сан-ки (sanqi), и его применение
BR112015015483A8 (pt) forma farmacêutica monolítica para a liberação modificada de uma combinação de ingredientes ativos e processo para produção da mesma